Comparative Pharmacology
Head-to-head clinical analysis: LUTATHERA versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUTATHERA versus MACROTEC.
LUTATHERA vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog that binds to somatostatin receptors (primarily subtype 2) with high affinity, resulting in internalization and intracellular retention of the radionuclide. The beta particle emission from Lu-177 causes DNA damage and cell death in somatostatin receptor-positive tumor cells.
Not applicable for diagnostic use.
7.4 GBq (200 mCi) intravenously every 8 weeks for 4 doses, with concomitant amino acid infusion for renal protection.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 3.5 days (84 hours) for the radioactive component (177Lu); clinically, this allows for prolonged tumor exposure and once-every-8-weeks dosing.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal excretion: approximately 50% of administered radioactivity excreted in urine within 24 hours, primarily as intact LUTATHERA and metabolites; fecal excretion: <5%.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical